Jazz Pharmaceuticals Plc · NASDAQ:JAZZ

Jazz Pharmaceuticals — 38th Annual J.P. Morgan Healthcare Conference (January 2020)

9 slides from Jazz Pharmaceuticals's conference presentation, Jan 14, 2020

  1. Slide 1: 38th Annual J.P. Morgan Healthcare Conference

    Meaghan Narcolepsy Patient th 38 Annual J.P. Morgan Healthcare Conference Bruce Cozadd, Chairman and CEO | January 13, 2020 NASDAQ: JAZZ © 2020 Jazz Pharmaceuticals all rights reserved.Meaghan Narcolepsy Patient th 38 Annual J.P. Morgan Healthcare Conference Bruce Cozadd, Chairman and CEO | January

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements “SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This slide deck and the accompanying oral presentation contain forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals’ future financial and oper

  3. Slide 3: Robust Evolution of Jazz Over Past 5 Years

    Robust Evolution of Jazz Over Past 5 Years BUSINESS EXPANSION, INCLUDING NEAR DOUBLING OF REVENUES 3 Key Commercialized Products 5 2 Total Revenues $1.2B $2.1-$2.2B 5 Launches Launches 1 Launch (since 2016) 2014 2019 Employees ~870 ~1,600 R&D Projects 8 > 25 1 2 R&D Spend as % of Revenues 6% 11-13%

  4. Slide 4: Broad Product Portfolio Contributing to Growing Revenues

    Broad Product Portfolio Contributing to Growing Revenues 2019 NET PRODUCT SALES PROJECTED INCREASE 11-15% OVER 2018 1 NET PRODUCT SALES $ in millions $1,600-$1,640 $160-$195 $1,405 $160-$180 $175 $149 $120-$135 $101 2 2 2 2 2018 2019G 2018 2019G 2018 2019G 2018 2019G Net Product Sales Charts Not Dra

  5. Slide 5: Strong Financial Execution

    Strong Financial Execution CONSISTENTLY DELIVERING MORE THAN 40% OF REVENUES TO THE BOTTOM LINE 1 ADJUSTED NET INCOME TOTAL REVENUES $15.50-$16.15 $2,100-$2,180 3 $ in millions PER DILUTED SHARE $1,891 $13.70 $1,619 $11.04 $1,488 $10.14 $1,325 $9.45 $1,173 $7.93 2 4 2014 2015 2016 2017 2018 2019G 20

  6. Slide 6: While Growing Our Commitment to R&D

    While Growing Our Commitment to R&D FOCUS ON DIVERSIFICATION OF PORTFOLIO LEADING TO EXPANDED INVESTMENT 1 1 TOTAL R&D SPEND R&D SPEND AS % OF TOTAL REVENUES $ in millions 11-13% $245-$265 10% 10% 10% $197 $162 7% $147 6% $97 $72 2 2 2014 2015 2016 2017 2018 2019G 2014 2015 2016 2017 2018 2019G 1 No

  7. Slide 7: Non-GAAP Financial Measures

    Non-GAAP Financial Measures To supplement Jazz Pharmaceuticals’ financial results and guidance presented in accordance with GAAP, the company uses certain non-GAAP (also referred to as adjusted or non-GAAP adjusted) financial measures in this presentation and the accompanying tables. In particular,

  8. Slide 8: Reconciliation of GAAP to Non-GAAP Adjusted Net Income

    Reconciliation of GAAP to Non-GAAP Adjusted Net Income In millions, except per share amounts 2019 2014 2015 2016 2017 2018 2 (unaudited) Financial Guidance 1 3 GAAP net income $ 58.4 $ 329.5 $ 396.8 $ 487.8 $ 447.1 $460 - $520 3 Intangible asset amortization 126.6 98.2 102.0 152.1 201.5 350 - 370 Sh

  9. Slide 9: Reconciliation of GAAP R&D to Non-GAAP Adjusted R&D Expense

    Reconciliation of GAAP R&D to Non-GAAP Adjusted R&D Expense In millions 2 2014 2015 2016 2017 2018 2019G (unaudited) 1 GAAP R&D expense $85.2 $135.3 $162.3 $198.4 $226.6 $267-$292 Share-based compensation expense (12.2) (13.4) (15.3) (17.9) (19.0) (22-27) Transaction and integration related costs (1

Jazz Pharmaceuticals — 38th Annual J.P. Morgan Healthcare Conference (January 2020) on 6ix